QNCX (Quince Therapeutics) Total Liabilities: $10.95 Mil (As of Mar. 2026)


QNCX Quince Therapeutics Inc QNCX
21 GF Score
Price $17.96
! 2 Warning Signs
View Full Analysis

What is Quince Therapeutics Total Liabilities?

Quince Therapeutics QNCX +2.75% 21 Total Liabilities is $10.95 Mil as of Mar. 2026. GuruFocus rates QNCX with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Quince Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $10.95 Mil.

Quince Therapeutics's quarterly Total Liabilities increased from Sep. 2025 ($108.84 Mil) to Dec. 2025 ($129.24 Mil) but then declined from Dec. 2025 ($129.24 Mil) to Mar. 2026 ($10.95 Mil).

Quince Therapeutics's annual Total Liabilities increased from Dec. 2023 ($82.82 Mil) to Dec. 2024 ($84.33 Mil) and increased from Dec. 2024 ($84.33 Mil) to Dec. 2025 ($129.24 Mil).

Quince Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Quince Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quince Therapeutics Total Liabilities Chart

Quince Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 14.64 3.32 82.82 84.33 129.24

Quince Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.51 105.47 108.84 129.24 10.95
QNCX
21GF Score
Quince Therapeutics Inc QNCX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quince Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Quince Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=43.226+(0.33+85.681
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=129.24

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=93.523--35.714
=129.24

Quince Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.768+(0.293+1.89
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=10.95

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=26.623-15.672
=10.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $10.95 Mil mean?
Quince Therapeutics (QNCX) has a Total Liabilities of $10.95 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Quince Therapeutics and its competitors.
Is Quince Therapeutics' Total Liabilities too high?
Quince Therapeutics' current Total Liabilities is $10.95 Mil. Overall, Quince Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Quince Therapeutics' Total Liabilities compare to ATOS and ZIVO?
Quince Therapeutics' Total Liabilities of $10.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Quince Therapeutics and its competitors. Quince Therapeutics's current Total Liabilities is $10.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quince Therapeutics stock overvalued right now?
Quince Therapeutics (QNCX) has a current Total Liabilities of $10.95 Mil. The current Total Liabilities is $10.95 Mil. Quince Therapeutics' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Quince Therapeutics (QNCX), the current Total Liabilities is $10.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quince Therapeutics Business Description

Address 611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
21GF Score

Get the complete analysis for QNCX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.96
Price